Spectrum Pharmaceuticals to Present Corporate Update at Credit Suisse 2012 Healthcare Conference in Phoenix on November 15th
<0> Spectrum PharmaceuticalsShiv Kapoor, 702-835-6300Vice President, Strategic Planning & Investor Relations </0>
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Credit Suisse 2012 Healthcare Conference being held at the Arizona Biltmore in Phoenix, Arizona. The Company presentation is on Thursday, November 15, 2012, at 8:30 AM MT.
A live webcast of Spectrum's presentation will be available at .
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum and its affiliates market three oncology drugs ─ FUSILEV (levoleucovorin) for Injection in the U.S.; FOLOTYN (pralatrexate injection), also marketed in the U.S.; and ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at .